Re: Siamak Daneshmand, Michiel S. Van der Heijden, Joseph M. Jacob, et al. TAR-200 for Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: Results from the Phase IIb SunRISe-1 Study. J Clin Oncol. In press. https://doi.org/10.1200/jco-25-01651
Re: Siamak Daneshmand, Michiel S. Van der Heijden, Joseph M. Jacob, et al. TAR-200 for Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: Results from the Phase IIb SunRISe-1 Study. J Clin Oncol. In press. https://doi.org/10.1200/jco-25-01651. // European Urology Focus. – URL: https://www.sciencedirect.com/science/article/pii/S240545692500286X?dgcid=rss_sd_all
Re: Siamak Daneshmand, Michiel S. Van der Heijden, Joseph M. Jacob, et al. TAR-200 for Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: Results from the Phase IIb SunRISe-1 Study. J Clin Oncol. In press. https://doi.org/10.1200/jco-25-01651. European Urology Focus. https://www.sciencedirect.com/science/article/pii/S240545692500286X?dgcid=rss_sd_all
“Re: Siamak Daneshmand, Michiel S. Van der Heijden, Joseph M. Jacob, et al. TAR-200 for Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: Results from the Phase IIb SunRISe-1 Study. J Clin Oncol. In press. https://doi.org/10.1200/jco-25-01651.” European Urology Focus.
@article{article45499,
title = {Re: Siamak Daneshmand, Michiel S. Van der Heijden, Joseph M. Jacob, et al. TAR-200 for Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: Results from the Phase IIb SunRISe-1 Study. J Clin Oncol. In press. https://doi.org/10.1200/jco-25-01651},
journal = {European Urology Focus},
url = {https://www.sciencedirect.com/science/article/pii/S240545692500286X?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...